Acceleron Pharma to Participate in Two Healthcare Investor Conferences in May

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, today announced that senior management will participate in two upcoming healthcare investor conferences in May.

Conference Details:

Live audio webcasts for both conferences will be available on the "Events and Presentations" page in the Investors section on the Company's website (www.acceleronpharma.com). A replay of the webcasts will also be available on Acceleron's website.

About Acceleron

Acceleron discovers and develops novel therapies to treat a wide range of rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This innovative approach to drug discovery has generated four therapeutic candidates currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160426006846/en/

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
or
Media:
BMC Communications LLC
Brad Miles, 646-513-3125

Source: Acceleron Pharma

You May Also Be Interested In

• ROSEN, THE FIRST FILING FIRM, Encourages Sharecare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SHCR
• Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, and QuidelOrtho and Encourages Investors to Contact the Firm
• Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Sharecare, Inc. (SHCR)